Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27739386 | 0.86 | SMN1; SMN2 (0.53) | RAB9ASMN1; SMN2NPC1GAAMEN1 | |
| SCHEMBL14932283 | 0.85 | RAB9A (0.52) | RAB9ASMN1; SMN2NPC1GAAMEN1 | |
| SCHEMBL10730199 | 0.80 | RAB9A (0.47) | RAB9ASMN1; SMN2NPC1GAAMEN1 | |
| SCHEMBL16218259 | 0.79 | ALOX5 (0.57) | RAB9ASMN1; SMN2NPC1GAAMAPT | |
| SCHEMBL27718331 | 0.78 | HPGD (0.52) | RAB9ASMN1; SMN2NPC1GAAMEN1 | |
| SCHEMBL10730213 | 0.78 | MAPK1 (0.51) | RAB9ASMN1; SMN2NPC1GAAMEN1 | |
| SCHEMBL14155832 | 0.77 | POLB (0.60) | RAB9ASMN1; SMN2NPC1GAAMEN1 | |
| SCHEMBL27443616 | 0.77 | ALOX5 (0.53) | RAB9ASMN1; SMN2NPC1GAAMEN1 | |
| SCHEMBL211598 | 0.77 | ALDH1A1 (0.69) | RAB9ASMN1; SMN2NPC1GAAMEN1 | |
| SCHEMBL3401066 | 0.76 | SMN1; SMN2 (0.56) | RAB9ASMN1; SMN2NPC1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773207-B1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2773207-B1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-03-07 | — | — | EP | disclosed |
| US-9221809-B2 | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221809-B2 | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221809-B2 | Aminopyrimidinones as interleukin receptor-associated kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140329799-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-11-06 | — | — | US | disclosed |
| US-20140329799-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-11-06 | — | — | US | disclosed |
| US-20140329799-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2014-11-06 | — | — | US | disclosed |
| EP-2773207-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013066729-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013066729-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-0101897-B1 | HETEROCYCLIC COMPOUNDS | BAYER AG (DE) | 1988-06-15 | — | — | EP | disclosed |
| EP-0101897-A1 | Heterocyclic compounds | BAYER AG (DE) | 1984-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329799-A1 | AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS | IRAK4, IRAK1, IRAK2 | RAB9A 1966/4885SMN1; SMN2 4280/4885NPC1 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.